Market Overview:
Escitalopram Tablets are the most prescribed antidepressant in the world. It is used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, and social anxiety disorder. Escitalopram is available in 5mg, 10mg and 20mg dosages. The market for global escitalopram tablets is expected to grow at a CAGR of 6% from 2018 to 2030. Some of the factors that are driving the growth of this market include increasing prevalence of depression and other psychiatric disorders, growing awareness about mental health issues among people, and rising demand for novel antidepressants. However, patent expirations of key drugs in this category could restrain the growth of this market to some extent during the forecast period.
Product Definition:
Escitalopram Tablets is a medicine that is used to treat depression and anxiety.
5mg/Pcs:
5mg/Pcs is a combination of two drugs, Escitalopram and Fluoxetine. It's used to treat depression and anxiety disorders. The drug works by restoring the balance between excitation and inhibition in the brain which is lost during depression.
The global market for 5mg/Pcs was valued at USD 743 million in 2016 and it's expected to grow at a CAGR of XX% over the forecast period.
10mg/Pcs:
10mg/Pcs is the average dosage of Escitalopram Tablets used for treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). It is also used to treat some symptoms of Alzheimer’s disease. According to the American Psychiatric Association, MDD was ranked as the sixth leading cause for deaths in U.S.
Application Insights:
Based on the application, the global escitalopram tablets market is segmented into children, adults and other applications. The other applications include elderly people suffering from depression or anxiety disorders and patients of sexual abuse trauma & PTSD. In terms of revenue, the adult application segment dominated the global market in 2017 owing to high prevalence rates of depression across all age groups globally. According escitalopram 20mg/pcs to WHO around half of all depressions cases are experienced by individuals above 18 years old worldwide.
The child application segment is expected to grow at a significant rate over forecast period due to increasing awareness about mental health issues among parents regarding their children especially in developed countries like U.S., Canada and Australia where access to healthcare is easy for everyone through public or private insurance plans supported by government run programs such as Medicare (U.S.) or Medibank (Australia).
Regional Analysis:
Europe dominated the global market in 2017 owing to high demand for antidepressants and increasing cases of depression. In addition, growing awareness about mental health disorders among people is expected to fuel the regional market growth over the forecast period. Asia Pacific is expected to be one of the fastest-growing regions due escitalopram hydrobromide being a new compound and availability of generic version in some Asian countries such as China, India, & Japan. Moreover, increasing disposable income levels coupled with rising consumer awareness regarding treatment options will drive regional growth over the forecast period.
The U.S., which was at forefront throughout most part of 2016 has now been replaced by Europe as it was first introduced in that region; however it still remains dominant due to its large population base along with higher R&D investment by companies operating within this region compared others globally (North America).
Growth Factors:
- Escitalopram Tablets is a cost-effective drug for the treatment of depression and anxiety disorders.
- Escitalopram Tablets has a favorable safety and tolerability profile, which makes it an attractive option for patients with these conditions.
- The drug is available in both generic and brand formulations, providing patients with multiple options to choose from.
- Escitalopram Tablets is approved by the FDA for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD).
- The growing awareness about mental health disorders and their treatments will continue to drive the growth of the Escitalopram Tablets market in years to come
Scope Of The Report
Report Attributes
Report Details
Report Title
Escitalopram Tablets Market Research Report
By Type
5mg/Pcs, 10mg/Pcs, 20mg/Pcs
By Application
Children, Adults
By Companies
Lundbeck (DK), Amneal Pharmaceuticals (US), Forest Laboratories (US), TEVA (Israel), Mylan (US), Silarx Pharmacueticals (US), Apotex (CA), Lupin (IN), Novartis (US), Hikma Pharmaceuticals (UK), Aurobindo Pharma (IN), Hetero Drugs (IN), Accord Healthcare (IN), Macleods Pharmaceuticals (IN), Xian Janssen Pharmaceutical (CN), Jewim Pharmaceutical (Shandong), Sichuan Kelun Pharmaceutical (CN), Hunan Dongting Pharmaceutical (CN), Zhejiang Conba Pharmaceutical (CN), Xidian Pharmaceutical (CN), Zhejiang Huahai Pharmaceutical (CN)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
208
Number of Tables & Figures
146
Customization Available
Yes, the report can be customized as per your need.
Global Escitalopram Tablets Market Report Segments:
The global Escitalopram Tablets market is segmented on the basis of:
Types
5mg/Pcs, 10mg/Pcs, 20mg/Pcs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adults
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lundbeck (DK)
- Amneal Pharmaceuticals (US)
- Forest Laboratories (US)
- TEVA (Israel)
- Mylan (US)
- Silarx Pharmacueticals (US)
- Apotex (CA)
- Lupin (IN)
- Novartis (US)
- Hikma Pharmaceuticals (UK)
- Aurobindo Pharma (IN)
- Hetero Drugs (IN)
- Accord Healthcare (IN)
- Macleods Pharmaceuticals (IN)
- Xian Janssen Pharmaceutical (CN)
- Jewim Pharmaceutical (Shandong)
- Sichuan Kelun Pharmaceutical (CN)
- Hunan Dongting Pharmaceutical (CN)
- Zhejiang Conba Pharmaceutical (CN)
- Xidian Pharmaceutical (CN)
- Zhejiang Huahai Pharmaceutical (CN)
Highlights of The Escitalopram Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5mg/Pcs
- 10mg/Pcs
- 20mg/Pcs
- By Application:
- Children
- Adults
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Escitalopram Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Escitalopram tablets are a medication used to treat depression. They work by increasing the levels of serotonin in the brain.
Some of the major companies in the escitalopram tablets market are Lundbeck (DK), Amneal Pharmaceuticals (US), Forest Laboratories (US), TEVA (Israel), Mylan (US), Silarx Pharmacueticals (US), Apotex (CA), Lupin (IN), Novartis (US), Hikma Pharmaceuticals (UK), Aurobindo Pharma (IN), Hetero Drugs (IN), Accord Healthcare (IN), Macleods Pharmaceuticals (IN), Xian Janssen Pharmaceutical (CN), Jewim Pharmaceutical (Shandong), Sichuan Kelun Pharmaceutical (CN), Hunan Dongting Pharmaceutical (CN), Zhejiang Conba Pharmaceutical (CN), Xidian Pharmaceutical (CN), Zhejiang Huahai Pharmaceutical (CN).
The escitalopram tablets market is expected to register a CAGR of 6%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Escitalopram Tablets Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Escitalopram Tablets Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Escitalopram Tablets Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Escitalopram Tablets Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Escitalopram Tablets Market Size & Forecast, 2018-2028
4.5.1 Escitalopram Tablets Market Size and Y-o-Y Growth
4.5.2 Escitalopram Tablets Market Absolute $ Opportunity
Chapter 5 Global Escitalopram Tablets Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Escitalopram Tablets Market Size Forecast by Type
5.2.1 5mg/Pcs
5.2.2 10mg/Pcs
5.2.3 20mg/Pcs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Escitalopram Tablets Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Escitalopram Tablets Market Size Forecast by Applications
6.2.1 Children
6.2.2 Adults
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Escitalopram Tablets Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Escitalopram Tablets Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Escitalopram Tablets Analysis and Forecast
9.1 Introduction
9.2 North America Escitalopram Tablets Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Escitalopram Tablets Market Size Forecast by Type
9.6.1 5mg/Pcs
9.6.2 10mg/Pcs
9.6.3 20mg/Pcs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Escitalopram Tablets Market Size Forecast by Applications
9.10.1 Children
9.10.2 Adults
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Escitalopram Tablets Analysis and Forecast
10.1 Introduction
10.2 Europe Escitalopram Tablets Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Escitalopram Tablets Market Size Forecast by Type
10.6.1 5mg/Pcs
10.6.2 10mg/Pcs
10.6.3 20mg/Pcs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Escitalopram Tablets Market Size Forecast by Applications
10.10.1 Children
10.10.2 Adults
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Escitalopram Tablets Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Escitalopram Tablets Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Escitalopram Tablets Market Size Forecast by Type
11.6.1 5mg/Pcs
11.6.2 10mg/Pcs
11.6.3 20mg/Pcs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Escitalopram Tablets Market Size Forecast by Applications
11.10.1 Children
11.10.2 Adults
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Escitalopram Tablets Analysis and Forecast
12.1 Introduction
12.2 Latin America Escitalopram Tablets Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Escitalopram Tablets Market Size Forecast by Type
12.6.1 5mg/Pcs
12.6.2 10mg/Pcs
12.6.3 20mg/Pcs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Escitalopram Tablets Market Size Forecast by Applications
12.10.1 Children
12.10.2 Adults
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Escitalopram Tablets Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Escitalopram Tablets Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Escitalopram Tablets Market Size Forecast by Type
13.6.1 5mg/Pcs
13.6.2 10mg/Pcs
13.6.3 20mg/Pcs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Escitalopram Tablets Market Size Forecast by Applications
13.10.1 Children
13.10.2 Adults
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Escitalopram Tablets Market: Competitive Dashboard
14.2 Global Escitalopram Tablets Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Lundbeck (DK)
14.3.2 Amneal Pharmaceuticals (US)
14.3.3 Forest Laboratories (US)
14.3.4 TEVA (Israel)
14.3.5 Mylan (US)
14.3.6 Silarx Pharmacueticals (US)
14.3.7 Apotex (CA)
14.3.8 Lupin (IN)
14.3.9 Novartis (US)
14.3.10 Hikma Pharmaceuticals (UK)
14.3.11 Aurobindo Pharma (IN)
14.3.12 Hetero Drugs (IN)
14.3.13 Accord Healthcare (IN)
14.3.14 Macleods Pharmaceuticals (IN)
14.3.15 Xian Janssen Pharmaceutical (CN)
14.3.16 Jewim Pharmaceutical (Shandong)
14.3.17 Sichuan Kelun Pharmaceutical (CN)
14.3.18 Hunan Dongting Pharmaceutical (CN)
14.3.19 Zhejiang Conba Pharmaceutical (CN)
14.3.20 Xidian Pharmaceutical (CN)
14.3.21 Zhejiang Huahai Pharmaceutical (CN)
